Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric K Rowinsky

Showing results (11-20 of 113) with videos related to

Pageof 12
Sort By:
Current Oncology Reports|February 19, 2005
Clinical experience with monoclonal antibodies to epidermal growth factor receptorEmiliano Calvo, Eric K Rowinsky
Cancer Investigation|May 25, 2002
Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitorsDesirée Hao, Eric K Rowinsky
Seminars in Oncology|August 8, 2006
Novel agents that target tublin and related elementsEric K Rowinsky, Emiliano Calvo
Cancer Biology & Therapy|September 26, 2003
Novel anticancer agents in clinical developmentAlex A Adjei, Eric K Rowinsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Raf: a strategic target for therapeutic development against cancerMuralidhar Beeram, Amita Patnaik, Eric K Rowinsky
British Medical Bulletin|November 8, 2002
Therapeutics targeting signal transduction for patients with colorectal carcinomaJohann S de Bono, Eric K Rowinsky
Trends in Molecular Medicine|April 3, 2002
The ErbB receptor family: a therapeutic target for cancerJohann S de Bono, Eric K Rowinsky
Clinical Breast Cancer|July 17, 2003
Mammalian target of rapamycin: a new molecular target for breast cancerMonica M Mita, Alain Mita, Eric K Rowinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapyHagop Youssoufian, Daniel J Hicklin, Eric K Rowinsky
Cancer Biology & Therapy|September 26, 2003
The molecular target of rapamycin (mTOR) as a therapeutic target against cancerMonica M Mita, Alain Mita, Eric K Rowinsky
Pageof 12

Showing results (11-20 of 113) with videos related to

Sort By:
Pageof 12
Current Oncology Reports|February 19, 2005
Clinical experience with monoclonal antibodies to epidermal growth factor receptorEmiliano Calvo, Eric K Rowinsky
Cancer Investigation|May 25, 2002
Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitorsDesirée Hao, Eric K Rowinsky
Seminars in Oncology|August 8, 2006
Novel agents that target tublin and related elementsEric K Rowinsky, Emiliano Calvo
Cancer Biology & Therapy|September 26, 2003
Novel anticancer agents in clinical developmentAlex A Adjei, Eric K Rowinsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Raf: a strategic target for therapeutic development against cancerMuralidhar Beeram, Amita Patnaik, Eric K Rowinsky
British Medical Bulletin|November 8, 2002
Therapeutics targeting signal transduction for patients with colorectal carcinomaJohann S de Bono, Eric K Rowinsky
Trends in Molecular Medicine|April 3, 2002
The ErbB receptor family: a therapeutic target for cancerJohann S de Bono, Eric K Rowinsky
Clinical Breast Cancer|July 17, 2003
Mammalian target of rapamycin: a new molecular target for breast cancerMonica M Mita, Alain Mita, Eric K Rowinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapyHagop Youssoufian, Daniel J Hicklin, Eric K Rowinsky
Cancer Biology & Therapy|September 26, 2003
The molecular target of rapamycin (mTOR) as a therapeutic target against cancerMonica M Mita, Alain Mita, Eric K Rowinsky
Pageof 12